🟢 Ionis Pharmaceuticals is trading 4.6% up in pre-market after FDA approval of Hibsago

Ionis Pharmaceuticals is trading 4.6% up at $47.49 before the October 21, 2026 market open after FDA approval of Hibsago (bepirovirsen). - FDA approved Hibsago October 20 for certain adults with chronic hepatitis B; GSK partnered in development. - Ionis licensed it to GSK; eligible for additional regulatory and sales milestones and 10–12% tiered net-sales royalties. - Shares gained 2.3% October 20; Reuters reported approval. The catalyst is company-specific, not solely the supplied biotech-sector rally; no pre-market volume data provided.